+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometrial Cancer Treatment Market by Treatment Type (Chemotherapy, Combination Therapy, Hormone Therapy), Drug Class (Antiangiogenic Therapy, Chemotherapeutic Agents, Hormonal Therapy), Line Of Therapy, Mode Of Administration, Administration Setting - Global Forecast 2025-2030- Product Image
Endometrial Cancer Treatment Market by Treatment Type (Chemotherapy, Combination Therapy, Hormone Therapy), Drug Class (Antiangiogenic Therapy, Chemotherapeutic Agents, Hormonal Therapy), Line Of Therapy, Mode Of Administration, Administration Setting - Global Forecast 2025-2030- Product Image
Sale

Endometrial Cancer Treatment Market by Treatment Type (Chemotherapy, Combination Therapy, Hormone Therapy), Drug Class (Antiangiogenic Therapy, Chemotherapeutic Agents, Hormonal Therapy), Line Of Therapy, Mode Of Administration, Administration Setting - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888365
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The endometrial cancer treatment market is experiencing a period of accelerated transformation, shaped by advances in precision medicine, evolving care pathways, and increased collaboration across global healthcare sectors. This report provides strategic intelligence tailored for senior healthcare decision-makers navigating this complex environment.

Market Snapshot: Endometrial Cancer Treatment Market Overview

The Endometrial Cancer Treatment Market grew from USD 8.87 billion in 2024 to USD 9.38 billion in 2025. It is expected to continue growing at a CAGR of 5.50%, reaching USD 12.24 billion by 2030. Growth is closely linked to increased adoption of targeted therapies, evolving clinical protocols, and greater emphasis on patient-centric approaches in major healthcare geographies. Forward-looking healthcare organizations are leveraging innovation, operational agility, and data-driven care strategies to capture new growth opportunities in this expanding segment.

Scope & Segmentation

This comprehensive analysis examines all critical segments and geographic dynamics influencing the endometrial cancer treatment landscape. Market coverage includes:

  • Treatment Types: Chemotherapy, Combination Therapy, Hormone Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Drug Classes: Antiangiogenic Therapy; Chemotherapeutic Agents including Platinum Based Agents and Taxanes; Hormonal Therapy such as Aromatase Inhibitors and Progestins; Immunotherapy with CTLA-4 Inhibitors and PD-1 Inhibitors; Targeted Therapy featuring MTOR Inhibitors, PARP Inhibitors, and Tyrosine Kinase Inhibitors.
  • Line of Therapy: First Line, Second Line, Third Line, and Fourth Line and Beyond.
  • Mode of Administration: Intravenous and Oral.
  • Administration Setting: Ambulatory Care, Hospital Inpatient, and Hospital Outpatient environments.
  • Regions: Americas (notably the United States, Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (including major economies like the United Kingdom, Germany, France, and emerging markets), and Asia-Pacific (covering China, India, Japan, Australia, and others).
  • Key Companies: Merck & Co., Inc.; GlaxoSmithKline plc; Eisai Co., Ltd.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; AstraZeneca PLC; Pfizer Inc.; Novartis AG; Johnson & Johnson; Eli Lilly and Company.

Key Takeaways Shaping the Market

  • Comprehensive adoption of molecular diagnostics is enabling earlier detection and improved risk stratification, providing a foundation for precision-guided care tailored to individual patient profiles.
  • Integration of immunotherapies and advanced targeted agents within existing treatment regimens is enhancing response durability and addressing tumor heterogeneity in diverse clinical settings.
  • Advancements in companion diagnostics and next-generation sequencing are supporting real-time monitoring of both treatment response and resistance, promoting agile, data-driven caregiving models.
  • Multidisciplinary collaboration among oncologists, surgeons, and diagnostic specialists ensures personalized and efficient care pathways, optimizing clinical and operational outcomes.
  • Regional partnerships between multinational leaders and emerging biotech firms are accelerating technology transfer, driving innovation, and expanding local manufacturing capacity, particularly in Asia-Pacific and Europe.

Evaluating Tariff Impact on the Endometrial Cancer Treatment Ecosystem

Planned United States tariffs on pharmaceutical imports in 2025 are anticipated to introduce further complexity to global supply chains, with potential effects on costs and procurement strategies for endometrial cancer treatment. Industry participants are actively pursuing regional sourcing, strategic partnerships, and logistics optimization to mitigate financial and operational pressures. Collaborative scenario planning among manufacturers, payers, and healthcare providers aims to ensure treatment continuity and affordability, safeguarding patient access despite tariff-related uncertainties.

Methodology & Data Sources

This analysis employs a rigorous, multi-phase research approach: secondary research leveraging peer-reviewed publications, clinical trials, and regulatory sources; primary research through interviews and surveys conducted with leading oncologists, pathologists, and policymakers; and expert workshops synthesizing findings into actionable strategies. Triangulation of qualitative and quantitative insights ensures a robust evidence base.

Why This Report Matters

  • Equips senior decision-makers with validated strategic insights across all treatment modalities, administration settings, and regions, supporting informed investment and partnership decisions.
  • Enables organizations to anticipate challenges posed by regulatory and economic shifts—including tariffs—while optimizing clinical, operational, and supply chain strategies.
  • Provides a forward-looking framework for prioritizing precision diagnostics, multidisciplinary care, and patient access initiatives in competitive healthcare markets.

Conclusion

This report delivers strategic clarity to those seeking to capture value from ongoing advances in endometrial cancer treatment. Senior leaders are empowered to drive innovation and resilience across the global treatment ecosystem. Leverage these insights to position your organization for future growth and evolving clinical standards.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of immunotherapy combinations targeting PD-1 and novel checkpoints in advanced endometrial cancer
5.2. Integration of molecular profiling and genomic biomarkers for personalized endometrial cancer treatment strategies
5.3. Increased adoption of minimally invasive robotic-assisted hysterectomy for early-stage endometrial cancer patients
5.4. Development of oral targeted therapies inhibiting PI3K/AKT/mTOR pathway in recurrent endometrial carcinoma management
5.5. Implementation of sentinel lymph node mapping to reduce surgical morbidity in endometrial cancer staging
5.6. Utilization of real-world evidence databases to optimize treatment algorithms and patient outcomes in endometrial cancer
5.7. Emergence of combination strategies pairing VEGF inhibitors with chemotherapy in high-risk endometrial cancer trials
5.8. Growth of digital health platforms for remote monitoring of quality of life and adverse events in endometrial cancer patients
5.9. Advances in radiotherapy techniques such as brachytherapy boost integration for localized endometrial carcinoma
5.10. Focus on disparities research addressing access to novel therapeutics in underserved endometrial cancer populations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Endometrial Cancer Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Combination Therapy
8.4. Hormone Therapy
8.5. Immunotherapy
8.6. Radiation Therapy
8.7. Surgery
8.8. Targeted Therapy
9. Endometrial Cancer Treatment Market, by Drug Class
9.1. Introduction
9.2. Antiangiogenic Therapy
9.3. Chemotherapeutic Agents
9.3.1. Platinum Based Agents
9.3.2. Taxanes
9.4. Hormonal Therapy
9.4.1. Aromatase Inhibitors
9.4.2. Progestins
9.5. Immunotherapy
9.5.1. CTLA-4 Inhibitors
9.5.2. PD-1 Inhibitors
9.6. Targeted Therapy
9.6.1. MTOR Inhibitors
9.6.2. PARP Inhibitors
9.6.3. Tyrosine Kinase Inhibitors
10. Endometrial Cancer Treatment Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Fourth Line And Beyond
10.4. Second Line
10.5. Third Line
11. Endometrial Cancer Treatment Market, by Mode Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Endometrial Cancer Treatment Market, by Administration Setting
12.1. Introduction
12.2. Ambulatory Care
12.3. Hospital Inpatient
12.4. Hospital Outpatient
13. Americas Endometrial Cancer Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Endometrial Cancer Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Endometrial Cancer Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Eisai Co., Ltd.
16.3.4. Bristol-Myers Squibb Company
16.3.5. F. Hoffmann-La Roche Ltd
16.3.6. AstraZeneca PLC
16.3.7. Pfizer Inc.
16.3.8. Novartis AG
16.3.9. Johnson & Johnson
16.3.10. Eli Lilly and Company
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ENDOMETRIAL CANCER TREATMENT MARKET: RESEARCHAI
FIGURE 26. ENDOMETRIAL CANCER TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. ENDOMETRIAL CANCER TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. ENDOMETRIAL CANCER TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 130. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 131. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 132. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 133. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 134. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 135. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 138. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 139. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 140. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 141. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 144. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 156. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 157. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 158. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 159. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 242. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 243. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 244. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 245. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 246. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 247. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 248. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 249. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 250. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 251. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 254. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 260. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 261. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 262. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 263. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 266. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 267. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 268. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 269. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 272. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025-2030 (USD MILLION)
TABLE 291. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 292. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 293. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
TABLE 296. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2025-2030 (USD MILLION)
TABLE 297. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
TABLE 298. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2025-2030 (USD MILLION)
TABLE 299. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 300. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLIO

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Endometrial Cancer Treatment market report include:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Eisai Co., Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.38 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.24 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Endometrial Cancer Treatment - Global Strategic Business Report - Product Image

Endometrial Cancer Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Endometrial Cancer Treatment Market Report 2025 - Product Image

Endometrial Cancer Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Endometrial Cancer - Pipeline Insight, 2025 - Product Image

Endometrial Cancer - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report - Product Image

Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Uterine Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Uterine Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Endometrial Cancer Drug Market

The Endometrial Cancer Drug market is a subset of the Uterine Cancer Drugs market, which is composed of drugs used to treat endometrial cancer, a type of cancer that affects the lining of the uterus. Endometrial cancer drugs are typically used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to reduce the amount of estrogen in the body, while chemotherapy is used to kill cancer cells. Targeted therapy is used to target specific cancer cells, while immunotherapy is used to boost the body's immune system to fight cancer. Some companies in the Endometrial Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.